Fitch
JACKSON, Miss. (Legal Newsline) – Private lawyers, some of whom contributed to her campaign, stand to gain financially from Mississippi Attorney General Lynn Fitch’s new lawsuit against 3M, DuPont and other companies over chemicals known as PFAS.
Fitch and three private firms filed their case Dec. 17 in a multidistrict litigation proceeding in South Carolina federal court. Those firms are headlined by Dallas’ Baron & Budd, a firm whose lawyers were among many in the trial bar to support the Republican Fitch’s 2019 campaign to replace Democrat Jim Hood. A lot of those firms handle securities class actions and see the Mississippi public employees pension system as a potential client.
The medical technology sector has performed well during 2020, benefitting from broader healthcare tailwinds.
The sector has many high-quality growth names that are well-placed to gain 2021 that Bank of America prefers over some of the big value names.
Here are the 16 medtech stocks BofA thinks you should own going into 2021.
Medical technology stocks performed strongly in 2020, benefitting from the wider healthcare tailwinds caused by the pandemic, and this is set to continue into 2021 for companies in the sector with strong fundamentals, according to Bank of America.
Healthcare companies have been at the top of the agenda throughout the pandemic, with the likes of drugmakers Pfizer, Moderna and AstraZeneca making the headlines with their COVID-19 vaccine candidates that have been at the fore of every investor s mind over the last month.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 .
ChemoCentryx, Inc.December 21, 2020 GMT
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment
The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for Disease Chronicity (measuring progression of fibrosis) shows significant benefit for avacopan versus placebo
CTHealthLink Expands Health Information Exchange Network To Include Yale New Haven Health and UCONN Health
Share Article
The new health system connections are a part of a growing list that make up CTHealthLink s physician-led health information network NEW HAVEN, Conn. (PRWEB) December 22, 2020 CTHealthLink (CTHL), the Connecticut State Medical Society’s (CSMS) robust health information exchange announced today they have added connections to Yale New Haven Health and UConn Health through the eHealth Exchange.
“The connections to Yale New Haven and UCONN are important milestones for Connecticut physicians and their patients,” said Dr. Robert Aseltine, a UConn Health professor who chairs the CTHL Advisory Board. “These connections allow Connecticut healthcare providers to gain access to critical patient data from hospitals, clinics, and practices, data that are needed to provide safe and comprehensive ca
Share:
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment
The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for Disease Chronicity (measuring progression of fibrosis) shows significant benefit for avacopan versus placebo
Avacopan safe and well tolerated in C3G patients
ChemoCentryx and VFMCRP plan to discuss registration pathway with regulatory agencies in US and EU
Conference call today at 4:30 pm Eastern Time